S&P 500   2,999.26 (+1.12%)
DOW   27,043.36 (+0.96%)
QQQ   193.48 (+1.25%)
AAPL   235.84 (-0.01%)
FB   189.70 (+3.50%)
MSFT   141.41 (+1.33%)
GOOGL   1,241.80 (+1.97%)
AMZN   1,759.68 (+1.34%)
NVDA   198.57 (+6.45%)
MU   46.37 (+3.37%)
BABA   176.43 (+3.08%)
GE   8.87 (+1.60%)
TSLA   258.55 (+0.62%)
T   37.91 (+1.17%)
ACB   3.79 (+7.98%)
NFLX   285.00 (-0.19%)
BAC   29.87 (+2.51%)
GILD   65.55 (+1.61%)
DIS   130.30 (+0.45%)
S&P 500   2,999.26 (+1.12%)
DOW   27,043.36 (+0.96%)
QQQ   193.48 (+1.25%)
AAPL   235.84 (-0.01%)
FB   189.70 (+3.50%)
MSFT   141.41 (+1.33%)
GOOGL   1,241.80 (+1.97%)
AMZN   1,759.68 (+1.34%)
NVDA   198.57 (+6.45%)
MU   46.37 (+3.37%)
BABA   176.43 (+3.08%)
GE   8.87 (+1.60%)
TSLA   258.55 (+0.62%)
T   37.91 (+1.17%)
ACB   3.79 (+7.98%)
NFLX   285.00 (-0.19%)
BAC   29.87 (+2.51%)
GILD   65.55 (+1.61%)
DIS   130.30 (+0.45%)
Log in

Luminex Stock Price, News & Analysis (NASDAQ:LMNX)

$20.26
+0.39 (+1.96 %)
(As of 10/15/2019 12:15 PM ET)
Today's Range
$19.91
Now: $20.26
$20.30
50-Day Range
$19.56
MA: $20.78
$22.59
52-Week Range
$19.32
Now: $20.26
$30.40
Volume29,206 shs
Average Volume169,717 shs
Market Capitalization$912.49 million
P/E Ratio42.20
Dividend Yield1.81%
Beta0.8
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$315.82 million
Cash Flow$1.03 per share
Book Value$10.49 per share

Profitability

Net Income$18.51 million

Miscellaneous

Employees988
Market Cap$912.49 million
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.


Luminex (NASDAQ:LMNX) Frequently Asked Questions

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Wednesday, July 31st. Shareholders of record on Thursday, September 26th will be given a dividend of $0.09 per share on Thursday, October 17th. This represents a $0.36 annualized dividend and a yield of 1.78%. The ex-dividend date is Wednesday, September 25th. This is a positive change from Luminex's previous quarterly dividend of $0.06. View Luminex's Dividend History.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings results on Wednesday, July, 31st. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.09. The medical instruments supplier had revenue of $83.06 million for the quarter, compared to analyst estimates of $81.61 million. Luminex had a negative return on equity of 0.78% and a negative net margin of 0.80%. Luminex's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the firm posted $0.15 earnings per share. View Luminex's Earnings History.

When is Luminex's next earnings date?

Luminex is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Luminex.

What guidance has Luminex issued on next quarter's earnings?

Luminex issued an update on its third quarter 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-83 million, compared to the consensus revenue estimate of $83.01 million.

What price target have analysts set for LMNX?

3 brokers have issued 12 month price targets for Luminex's stock. Their predictions range from $21.00 to $33.00. On average, they expect Luminex's share price to reach $27.00 in the next year. This suggests a possible upside of 33.3% from the stock's current price. View Analyst Price Targets for Luminex.

What is the consensus analysts' recommendation for Luminex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Has Luminex been receiving favorable news coverage?

Press coverage about LMNX stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Luminex earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Luminex.

Are investors shorting Luminex?

Luminex saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,000,000 shares, a drop of 30.6% from the August 30th total of 1,440,000 shares. Based on an average trading volume of 189,400 shares, the days-to-cover ratio is presently 5.3 days. Currently, 2.4% of the shares of the company are sold short. View Luminex's Current Options Chain.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Mondi (MNDI), Alphabet (GOOG), Intel (INTC), Micron Technology (MU), Nektar Therapeutics (NKTR), Rocket Pharmaceuticals (RCKT), Verizon Communications (VZ), Cree (CREE) and Ligand Pharmaceuticals (LGND).

Who are Luminex's key executives?

Luminex's management team includes the folowing people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

Who are Luminex's major shareholders?

Luminex's stock is owned by many different of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

Which major investors are buying Luminex stock?

LMNX stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View Insider Buying and Selling for Luminex.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $20.26.

How big of a company is Luminex?

Luminex has a market capitalization of $912.49 million and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

What is Luminex's official website?

The official website for Luminex is http://www.luminexcorp.com/.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


MarketBeat Community Rating for Luminex (NASDAQ LMNX)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  561
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel